Invivyd Inc. Launches New Discovery Program for Monoclonal Antibody Treatment Targeting Measles Infections
Invivyd Inc. has launched a new discovery program aimed at developing a monoclonal antibody treatment for measles infections. This initiative responds to healthcare providers' requests for therapeutic options due to declining vaccination rates, with over 20 million Americans unvaccinated. The program seeks to identify a preclinical candidate by 2025, with updates expected by year-end. This effort is part of Invivyd's broader research into monoclonal antibodies for COVID-19, RSV, and influenza.
Invivyd Inc. has announced the initiation of a new discovery program focused on developing a monoclonal antibody treatment for measles. This effort comes in response to requests from multiple healthcare providers seeking a therapeutic option for active measles infections and post-exposure prophylaxis amid declining vaccination rates. With over 20 million Americans unvaccinated against measles, this program aims to expedite the path towards the functional eradication of the virus. Invivyd plans to identify a preclinical measles monoclonal antibody candidate by 2025, with a progress update expected by the end of the year. This initiative complements Invivyd's ongoing discovery programs for next-generation COVID-19, RSV, and influenza monoclonal antibodies.
